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Gene CYP2B6 
The CYP2B6 G516T 
polymorphism has a major 
impact on the level of hepatic 
metabolism. 
Objectives 
Identify the G516Tpolymorphism located 
at exon 4 of the CYP2B6 gene in HIV-1 
or HVC/HBV co-infected patients. 
Review 
The CYP2B6 gene has been mapped in 
the context of chromosome 19,  and 
encodes a member of the enzyme 
superfamily, cytochrome P450 
monooxygenase (CYP450), which is 
located in the endoplasmic reticulum.  
This protein catalyses several 
reactions involved in drug metabolism. 
Many genetic disorders have been 
reporte as having influence on 
management, metabolism, distribution 
and elimination of drugs used in 
HIV/AIDS therapy (1).  
The G516T polymorphism in the 
CYP2B6 gene, present in exon 4, 
shows a major impact with clinical 
relevance on the level of hepatic 
metabolism, with consequently 
translates into changes in the 
respective plasmatic concentrations of 
drugs (2). 
This genetic variant results in the 
substitution of a guanine for a thymine 
at nucleotide 516 of the coding 
sequence wich leads to the amino acid 
substitution at position 172,  glutamine 
for histidine (Q172H) and whose  role 
in enzyme activity is still not clear.  
This has been described as a "non-
sense" polymorphism,  affecting  the 
metabolic activity by alteration of 
substrate binding or aberrant splicing, 
leading to a decreased amount of 
normal mRNA and thus reducing the 
levels of functional protein (3). 
 
 
Materials and Methods 
1ml blood of 27 
patients infected with 
HIV1 or co-infected 
with HBV/C 
Sample 
PerfectPure DNA 
Blood Kit (5Prime) 
Extraction of Genomic 
DNA 
• Primer Forward 
5´TGTTGTAGTGAGAGTT
CTG3´ 
• Primer Reverse 
3´GATAGGGACAGAGATG
GCAG5´ 
PCR Amplification 
• BLAST (Basic Local 
Alignment Search 
Tool)  
• BioEdit 
Sequencing Analyses 
Results 
The G516T genetic variant can occur in heterozygosity (GT) or homozygosity (TT). 
Subjects with homozygous T allele (TT) exhibit enzymatic activity at lower levels when 
compared to individuals homozygous for the G allele (GG). Individuals heterozygous (GT) 
have intermediate levels (4). 
Our results allow us to identify the presence of polymorphic mutation CYP2B6 G516T in 25 
patients, 8 of them carry the heterozygous genotype GT and 17 carry homozygous 
genotype TT.  
In the future, therapeutics for HIV can be set in compliance with the patient's genetic 
information, leading to reduced toxicity levels and improved patient compliance to 
treatment. 
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CYP2B6 
Polymorphism G516T 
2 G – G  
8 G – T 
17 T – T  
Fig. 1 - Gene CYP2B6 represented by exons and introns, the red 
triangle indicates the location of the SNP G516T, the substitution leads 
to Glu172His. The results of sequence alignment reveal the site of 
nucleotide substitution. 
 
Fig. 2  - 3D structure of native CYP2B6 protein, the  
SNP G516T is illustrated in green. Image acquired by 
VMD. 
  
25 patients present the G516T 
polymorphism on the CYP2B6 gene. 
 
